Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) have been assigned a consensus rating of "Moderate Buy" from the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $53.92.
Several research analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a report on Monday, August 15th. They issued a "buy" rating and a $40.00 price target on the stock. Credit Suisse Group raised their price target on shares of Kymera Therapeutics from $60.00 to $61.00 and gave the company an "outperform" rating in a report on Wednesday, August 10th. Morgan Stanley raised their price target on shares of Kymera Therapeutics from $35.00 to $37.00 and gave the company an "equal weight" rating in a report on Monday, August 29th. SVB Leerink initiated coverage on shares of Kymera Therapeutics in a research note on Wednesday, July 20th. They set a "market perform" rating and a $26.00 price objective on the stock. Finally, Wells Fargo & Company dropped their price objective on shares of Kymera Therapeutics from $62.00 to $35.00 and set an "overweight" rating on the stock in a research note on Wednesday, June 1st.
Get Kymera Therapeutics alerts:Kymera Therapeutics Stock Performance
KYMR opened at $21.69 on Monday. The company's 50 day simple moving average is $27.34 and its 200 day simple moving average is $26.73. Kymera Therapeutics has a 1 year low of $13.15 and a 1 year high of $69.12. The stock has a market capitalization of $1.19 billion, a PE ratio of -8.00 and a beta of 0.99.
Kymera Therapeutics (NASDAQ:KYMR – Get Rating) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.10). Kymera Therapeutics had a negative net margin of 245.69% and a negative return on equity of 31.52%. The business had revenue of $11.51 million during the quarter, compared to analysts' expectations of $14.97 million. During the same quarter in the previous year, the business posted ($0.55) EPS. The company's quarterly revenue was down 37.8% on a year-over-year basis. As a group, sell-side analysts expect that Kymera Therapeutics will post -2.68 earnings per share for the current fiscal year.Insider Transactions at Kymera Therapeutics
In related news, Director Bvf Partners L. P/Il purchased 545,525 shares of the firm's stock in a transaction dated Monday, August 22nd. The stock was acquired at an average price of $26.00 per share, with a total value of $14,183,650.00. Following the completion of the transaction, the director now owns 2,480,742 shares of the company's stock, valued at $64,499,292. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 17.01% of the company's stock.
Institutional Trading of Kymera Therapeutics
A number of hedge funds have recently made changes to their positions in KYMR. Nisa Investment Advisors LLC grew its position in shares of Kymera Therapeutics by 338.8% during the second quarter. Nisa Investment Advisors LLC now owns 2,137 shares of the company's stock worth $42,000 after buying an additional 1,650 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in Kymera Therapeutics during the first quarter valued at $53,000. Virtus ETF Advisers LLC increased its stake in Kymera Therapeutics by 147.4% during the second quarter. Virtus ETF Advisers LLC now owns 7,171 shares of the company's stock valued at $141,000 after purchasing an additional 4,273 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Kymera Therapeutics by 14.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,760 shares of the company's stock worth $159,000 after purchasing an additional 488 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Kymera Therapeutics during the second quarter worth $217,000.
Kymera Therapeutics Company Profile
(Get Rating)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Read More
- Get a free copy of the StockNews.com research report on Kymera Therapeutics (KYMR)
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.